SCHEMBL3542927

SCHEMBL3542927

CCCCCCCC[N]c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
DNM1 Q05193 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
TP53 P04637 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EPHX2 P34913 1/20 0.39
PKM P14618 1/20 0.39
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
HTT P42858 2/20 0.38
KCNH2 Q12809 1/20 0.38
NAAA Q02083 1/20 0.38
KCNA3 P22001 1/20 0.38
LIPG Q9Y5X9 1/20 0.37
SIGMAR1 Q99720 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6716782 1.00 MEN1 (0.40) MEN1KMT2ADNM1ALDH1A1CYP1A2
SCHEMBL5964912 1.00 MEN1 (0.40) MEN1KMT2ADNM1ALDH1A1CYP1A2
SCHEMBL6542019 1.00 MEN1 (0.40) MEN1KMT2ADNM1ALDH1A1CYP1A2
SCHEMBL1669437 1.00 MEN1 (0.40) MEN1KMT2ADNM1ALDH1A1CYP1A2
SCHEMBL96871 1.00 MEN1 (0.40) MEN1KMT2ADNM1ALDH1A1CYP1A2
SCHEMBL6717183 1.00 MEN1 (0.40) MEN1KMT2ADNM1ALDH1A1CYP1A2
SCHEMBL96272 0.98 LTA4H (0.38) MEN1KMT2ADNM1ALDH1A1CYP1A2
SCHEMBL49576 0.91 LTA4H (0.38) MEN1KMT2AALDH1A1SMN1; SMN2CES2
SCHEMBL95534 0.81 ALDH1A1 (0.41) MEN1KMT2AALDH1A1TP53MAPK1
Azobenzene SCHEMBL27918792 0.79 ALDH1A1 (0.60) MEN1KMT2ADNM1ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723522-B2 Pyridine derivative production method FUJIFILM FINECHEMICALS CO., LTD (JP) 2010-05-25 US disclosed
EP-1559711-B1 PREPARATION OF PYRIDINE DERIVATIVES USING PYRIMIDINIUM DERIVATIVES AS INTERMEDIATES FUJIFILM FINECHEMICALS CO LTD (JP) 2008-06-25 EP disclosed
US-6926943-B2 Use of light-absorbing compounds in the information layer of optical data carriers, and optical data carriers BAYER AKTIENGESELLSCHAFT (DE) 2005-08-09 US disclosed
US-20050171355-A1 Pyridine derivative production method SANKIO CHEMICAL CO., LTD. 2005-08-04 US disclosed
EP-1559711-A1 PREPARATION OF PYRIDINE DERIVATIVES USING PYRIMIDINIUM DERIVATIVES AS INTERMEDIATES Sankio Chemical Co., Ltd. (JP) 2005-08-03 EP disclosed
EP-1452574-A1 COMPOSITION FOR ORGANIC ELECTROLUMINESCENCE ELEMENT AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME TOYO INK MFG. CO., LTD. (JP) 2004-09-01 EP disclosed
US-20040151944-A1 Anode, cathode, light emitting layers TOYO INK MFG. CO., LTD. (JP) 2004-08-05 US disclosed
EP-0900790-B1 Triazine dithiol derivatives having a perfluoro group for treating metal surfaces UNIV IWATE (JP) 2004-06-23 EP disclosed
US-20030175616-A1 Optical recording media; high density writing LANXESS DEUTSCHLAND GMBH (DE) 2003-09-18 US disclosed
US-6117893-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 2000-09-12 US disclosed
EP-0900790-A1 Triazine thiol derivatives having a perfluoro group for treating metal surfaces Iwate University (JP) 1999-03-10 EP disclosed
US-5834501-A TREATING DIABETES OR HYPERLIPEMIA SANKYO COMPANY, LIMITED (JP) 1998-11-10 US disclosed
US-5739345-A HYPOGLYCEMIC AND ANTIDIABETIC AGENTS SANKYO COMPANY, LIMITED (JP) 1998-04-14 US disclosed
US-5624935-A ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS SANKYO COMPANY, LIMITED 1997-04-29 US disclosed
EP-0597287-B1 Process for the preparation of anthraquinones BASF AG (DE) 1996-04-10 EP disclosed
EP-0676398-A2 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO COMPANY LIMITED (JP) 1995-10-11 EP disclosed
US-5429918-A Antifading agent FUJI PHOTO FILM CO., LTD. (JP) 1995-07-04 US disclosed
US-5387704-A Preparation of anthraquinones BASF AKTIENGESELLSCHAFT (DE) 1995-02-07 US disclosed
EP-0597287-A1 Process for the preparation of anthraquinones BASF Aktiengesellschaft (DE) 1994-05-18 EP disclosed
US-4353734-A PRE- AND POSTEMERGENCE CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA R.T. (HU) 1982-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171355-A1 Pyridine derivative production method CPS1, NAT1, ACMSD MEN1 1682/4885KMT2A 1451/4885DNM1 680/4885
US-20030175616-A1 Optical recording media; high density writing RHOA, IK, YTHDF1 MEN1 2318/4885KMT2A 165/4885DNM1 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.